Real-World Outcomes in Myeloma Patients With t (11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database
Published: November 2025, Clinical Lymphoma Myeloma Leukemia
Salvage Autologous Stem Cell Transplantation Outcomes and The Use of Maintenance in Relapsed Multiple Myeloma: Real world evidence from the Canadian Myeloma Research Group Database
Published: October 2025, Clinical Lymphoma Myeloma Leukemia
Treatment Patterns and Outcomes of Multiple Myeloma Patients Undergoing Second-Line Therapy: A Canadian Myeloma Research Group (CMRG) Analysis
Published: July 2025, Clinical Lymphoma Myeloma Leukemia
Disease Characteristics and Outcomes of 493 Young Myeloma Patients Treated with Modern Therapies: A Canadian Myeloma Research Group Database Study
Published: November 2024, Cancer Medicine
Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial
Published: September 2024, Blood Cancer Journal
Tandem Autologous Stem Cell Transplantation Does Not Benefit High-Risk Myeloma Patients in the Maintenance Era: Real-World Results from The Canadian Myeloma Research Group Database
Published: September 2024, Transplantation and Cellular Therapy
Long-term follow-up of outcomes including progression-free survival 2 in patients with transplant-ineligible multiple myeloma in the real-world practice: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) database
Published: June 2024, eJHaem
Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial
Published: January 2024, Nature Medicine
Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database
Published: December 2023, Blood Cancer Journal
Outcome of carfilzomib/pomalidomide-based regimens after daratumumab-based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis
Published: November 2023, European Journal of Haematology
Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database
Published: September 2023, Blood Cancer Journal
A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients with Relapsed and Refractory Multiple Myeloma
Published: July 2023, Clinical Lymphoma Myeloma Leukemia
Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis
Published: July 2023, Blood Cancer Journal
Real-world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group Database
Published: February 2023, Cancer Medicine
Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database
Published: August 2022, eJHeam
Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group Database
Published: August 2022, Clinical Lymphoma Myeloma Leukemia
Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database
Published: April 2022, British Journal of Haematology
Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database
Published: March 2022, Current Oncology
Efficacy of Daratumumab-Containing Regimens Among Patients with Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis
Published: February 2022, Frontiers in Oncology
Efficacy of Daratumumab-Containing Regimens Among Patients with Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis
Published: February 2022, Frontiers in Oncology
Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada
Published: October 2021, European Journal of Haematology
The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database
Published: June 2021, Haematologica
Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN-003 single arm phase II trial
Published: May 2021, American Journal of Hematology
A descriptive cost-analysis of MCRN003, a phase 2 clinical trial evaluating high-dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma
Published: May 2021, European Journal of Haematology
Lenalidomide Maintenance After Autologous Stem Cell Transplant: The Utility of Real-World Data and Future Areas of Study
Published: March 2021, Journal of Cancer Immunology
The impact of lenalidomide maintenance on second-line chemotherapy in transplant eligible patients with multiple myeloma
Published: February 2021, European Journal of Hematology
Real-world outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant-ineligible multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group database
Published: February 2021, British Journal of Haematology